文献速递肝病

无利巴韦林的雷迪帕韦联合索磷布韦治疗肝移植受者HCV感染

Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin.
PubMed 文献 · Aliment Pharmacol Ther · 2017-04-06

这项回顾性研究分析了75例肝移植后基因1型HCV感染患者,采用雷迪帕韦/索磷布韦联合方案(不含利巴韦林)治疗。意向性分析显示SVR12达95.9%,仅第8周可检测到病毒载量预测治疗失败。作者认为该方案在肝移植受者中具有优异的SVR结局和良好的安全性、耐受性,尽管治疗指南推荐联用利巴韦林。

要点

  • 肝移植后基因1型HCV感染患者使用雷迪帕韦/索磷布韦(无利巴韦林)的SVR12为95.9%。
  • 单因素logistic回归中,仅第8周可检测到病毒载量预测未获得SVR。
  • 作者认为该方案结局优异且安全性、耐受性良好,尽管指南推荐联用利巴韦林。

核心结论

  • 作者认为,尽管治疗指南推荐使用利巴韦林,但无利巴韦林的雷迪帕韦/索磷布韦在肝移植后HCV感染受者中证实了优异的SVR结局和良好的安全性、耐受性。

研究设计与样本

  • 回顾性研究,纳入75例肝移植后接受无利巴韦林的雷迪帕韦联合索磷布韦治疗的患者,以意向性治疗(ITT)方式分析SVR队列间差异及SVR预测因素。

主要发现

  • 2014年10月至2015年8月本中心共408例基因1型HCV患者接受雷迪帕韦/索磷布韦治疗,其中73例为肝移植后患者,移植后中位治疗时间为2.9年。
  • 雷迪帕韦/索磷布韦获得95.9%的SVR12。
  • 队列中非裔美国人占28.8%,63%的患者既往接受过治疗(包括13.7%既往接受直接抗病毒药物治疗),仅2.7%存在移植物肝硬化复发,90.4%使用以钙调神经磷酸酶抑制剂为基础的免疫抑制治疗,约82%为慢性肾脏病(CKD)2期或3期。
  • 单因素logistic回归中,仅第8周可检测到病毒载量预测未获得SVR。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ledipasvir and sofosbuvir is a well-tolerated regimen with high sustained virological response (SVR) rates in pre-liver transplant patients infected with chronic hepatitis C virus (HCV), but data in liver transplant recipients outside of clinical trials is limited. AIM: To address this knowledge gap and assess SVR rates without the use of ribavirin in liver transplant recipients METHODS: This is a retrospective study examining the treatment of 75 post-liver transplant recipients with ledipasvir and sofosbuvir without ribavirin. Differences between SVR cohorts and predictors of SVR were analysed in an intention-to-treat (ITT) fashion. RESULTS: A total of 408 genotype 1, HCV patients were treated with ledipasvir/sofosbuvir from October 2014 to August 2015 at our centre. Seventy-three patients were post-liver transplant and were treated with a median of 2.9 years from transplant. Ledipasvir/sofosbuvir achieved an SVR12 of 95.9%. African Americans made up 28.8% of the cohort. Sixty-three per cent of patients were treated previously, including 13.7% of patients previously treated with direct-acting antivirals. Only 2.7% had recurrent allograft cirrhosis, and the majority (90.4%) was on calcineurin inhibitor based immunosuppressive therapy. Approximately 82% of patients had chronic kidney disease (CKD) stage 2 or 3. In univariate logistic regression, only detectable week 8 viral load was predictive of failure to achieve SVR. CONCLUSION: Our data confirm excellent SVR outcomes and favourable safety and tolerability profiles with ledipasvir/sofosbuvir without ribavirin in post-liver transplant recipients infected with HCV, despite treatment guidelines to use ribavirin.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Pillai AA, Maheshwari R, Vora R, et al. Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin. Aliment Pharmacol Ther. 2017. PMID: 28382751. doi:10.1111/apt.14059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。